Drug Approval | August 28, 2021
DCGI approves Enzene biosimilar Denosumab for Osteoporosis
This is Enzene Biosciences third biosimilar to be approved
This is Enzene Biosciences third biosimilar to be approved
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
